Company patents
Natera, Inc.
Natera, Inc. demonstrates a strong, albeit consolidating, focus on core pharma_biotech areas, with 'Genetic & Microbiological Assays' comprising 94.4% of its portfolio. While patenting in 'Genetic & Microbiological Assays' and 'Bioinformatics' saw significant growth in 2024 (YoY +158.8% and +81.8% respectively), the company also shows an emerging interest in 'Healthcare Informatics' (16.9% of portfolio), which experienced a remarkable 100.0% YoY growth in 2025, suggesting a strategic expansion into data-driven healthcare solutions despite a partial decline so far in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
124 US filings (since 2023) · 6 categories · 7 themes
Methods and reagents designed to improve the specificity, efficiency, or yield of nucleic acid capture, ligation, amplification, or library preparation steps, particularly for sequencing applications or quantitative analysis.
Computational methods and systems for analyzing biological data (e.g., genomic, proteomic, clinical) to diagnose diseases, predict patient prognosis, assess treatment response, or stratify patients for therapy.
Computational techniques and algorithms for processing, aligning, and interpreting raw biological sequence data (DNA, RNA, protein), including identifying genetic variations, classifying organisms, or predicting sequence attributes.
Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.
Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.
Patents
Showing 1-10 of 54
Rapid Isothermal Amplification